Month: July 2026

Release – Kuya Silver Achieves Record Q2 Production at Bethania Mine, Increasing Quarterly Tonnage by 66% and Posts Record Monthly Silver Production in June

Posted on by [email protected]
Corporate Logo

Research News and Market Data on KUYAF

All references to dollar amounts are references to U.S. Dollars, unless otherwise stated

Toronto, Ontario–(Newsfile Corp. – July 21, 2026) – Kuya Silver Corporation (CSE: KUYA) (OTCQB: KUYAF) (FSE: 6MR1) (the “Company” or “Kuya Silver“) is pleased to report record quarterly production and provide an operational update for the second quarter of 2026 at the Bethania silver project, which again delivered record daily and quarterly production rates as the ramp-up continued to show significant progress during the quarter. Although the short-term progress at Bethania is encouraging, preparations are underway for upward step change in production later this year as additional underground development is completed.

Operational Highlights

  • 5,097 metric tonnes of mineralized material mined at Bethania, a 66% increase quarter over quarter.
  • Record 23,912 oz silver (30,559 silver equivalent) processed during the quarter.
  • Record monthly production in June of 13,273 silver equivalent ounces as grades improved toward the end of the quarter.
  • Continued strong underground development with record 437 meters advanced while drilling and blasting 1,535 metric tonnes of development material to support the expansion of underground mining operations.
  • Silver production was 87% of the quarterly revenue from Bethania in Q2 with an average selling price of $72/oz.
  • The Company continued to develop partnerships with local contractors to accelerate our exploration and mine development objectives.

Kuya Silver Delivers Steady Progress at Bethania in Q2

Production of mineralized material at the Bethania Project totalled 5,097 metric tonnes, another quarterly record and a 66% improvement over Q1 2026 as production continues to steadily ramp up. Development activities achieved total of 437 metres of underground advancement and 1,535 tonnes of development material in the quarter. Kuya Silver achieved a record daily production of 124 tonnes and a record monthly production of 2,040 tonnes (68 tpd) in Q2, as well as a monthly record for silver production (13,273 oz Ag eq.) demonstrating that the Company’s methodical ramp-up process is generating positive results.

Silver recoveries averaged 79.7% during Q2 2026, directly reflecting the lower-grade development material and stope scheduling early in the quarter, which resulted in an average grade of 5.9 oz/t silver (8.8 oz/t or 274 g/t Ag equivalent). Mine sequencing optimizations implemented by the Kuya Silver team began delivering positive results mid-quarter. By June, silver grades increased to 6.66 oz/t exceeding management’s expectations, and silver recoveries improved to approximately 82%. Kuya Silver has previously achieved silver recoveries exceeding 90% when processing higher-grade batches, the Company expects recoveries to continue improving toward these levels as the mine reaches steady-state production. Furthermore, Kuya Silver has launched a metallurgical testing campaign to further optimize recoveries.

In addition, Kuya Silver approved the installation of a dual-car hoisting winch system at Bethania, expected to be commissioned in October 2026. This infrastructure upgrade is expected to improve efficiency of the mine’s ore extraction by enabling simultaneous haulage of two ore cars. This improvement will support the ongoing production ramp-up and provide flexibility and redundancy to materials handling as the Company advances the underground ramp project.

David Stein, Kuya Silver’s President and CEO, stated, “The ramp up strategy to produce at the Bethania mine while taking on ambitious mine development to expand production to our Phase 1 target of 350 tpd has allowed the Company to generate significant revenue and reduce our burn rate. The revenue from mining operations on top of the Company’s already strong balance sheet puts Kuya Silver in an excellent position, for the first time in our history, to deliver on its near-term production targets while at the same time expanding our exploration efforts to delineate more silver at the Bethania mine and the six other silver veins systems we control in the Bethania district.”



To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5945/305919_kuya-silver.jpg

Table 1: Production highlights from the Bethania silver mine

(1) Information has been revised from amounts previously disclosed in the Company’s press release dated April 22, 2026. The revisions relate primarily to the correction of previously reported production metrics.

(2) prices for silver equivalent calculations use period ending spot prices and are as follows: June 30, 2026 $61/oz, lead $1,877/tonne, zinc$3,552/tonne Mar. 31 2026 silver $74/oz, lead $1,909/tonne, zinc$3,230/tonne June 30, 2025 $36/oz, lead $2,205/tonne, zinc$2,764/tonne Mar. 31 2026 silver $74/oz, lead $1,909/tonne Mar. 31, 2025 period; silver $34/oz, gold $3122.80/oz, lead $2,002/tonne, zinc $2,829/tonne.

(3) includes only payable recovery i.e. lead in the silver- lead concentrate and zinc in the zinc concentrate and silver in both concentrates.

(4) may include provisional settlements at the end of the period, net of treatment and refining costs.

Developing Partnerships with Local Mining and Exploration Contractors

As part of its strategy to sustain production growth and expand exploration efforts at the Bethania project, Kuya Silver is in the process of onboarding up to three specialized contractors to support development, drilling and operations at the project. The underground drilling contract to operate three drill rigs at Bethania has been formally awarded to Safasermin S.A.C., an experienced Peruvian drilling and exploration contractor, pending the finalization of contract details. All three rigs are initially planned to operate underground at the Bethania mine; however, surface drilling is expected to be added and become a significant component of the drilling program during the second half of 2026.

Following a competitive bidding process, comprehensive site visits and final negotiations, Kuya Silver has issued a formal Letter of Award to Minera Tauro S.A.C. to perform additional underground development at the Bethania mine. The contractor has officially confirmed its acceptance. Pending final execution of the contract, Minera Tauro is expected to mobilize in the coming weeks to accelerate underground development. This partnership will allow Kuya Silver’s in-house operations staff to focus on achieving greater production levels as the ramp-up continues.

Kuya Silver has also commenced portal development for the new internal ramp project and advanced a rigorous, competitive bidding process to shift the majority of the ramp development to a specialized mining contractor. Following comprehensive site visits and detailed evaluations of the project’s technical data and Terms of Reference, Kuya Silver has finalized the receipt of complete technical and economic proposals from four highly respected mining contractors. The Company is currently evaluating the final submissions and expects to formally award the contract and mobilize the selected contractor shortly.

In parallel, Kuya Silver has completed a geomechanical assessment and ground-support design study for the ramp project, characterizing rock-mass conditions and establishing the optimal reinforcement system for each section of the planned corridor. This engineering work enables the Company to move directly from contractor award to mobilization without delay. The preparatory work is expected to provide greater confidence in both the execution timeline and the cost profile of this critical infrastructure investment.

Christian Aramayo, Kuya Silver’s Chief Operating Officer, remarked, “At Bethania, our development decisions are driven by geology, not short-term price volatility. We are partnering with elite contractors and expanding our team to optimize development ahead of completing our Phase 1 ramp-up. We are committing to disciplined, high-return infrastructure, such as advancing our new internal ramp project, to unlock the deeper, and higher-grade vein structures within the Bethania system. Our strong balance sheet allows us to build our infrastructure the right way, ensuring we develop a safe and flexible operation, capable of maximizing the margin of every ounce we mine.”

Camila Plant Update

Kuya Silver continues to process its mineralized material at the Camila Plant. The Company announced an LOI on January 27, 2026 (see press release) and plans to make a separate announcement.

Support for Local Districts and Earthquake Relief Efforts

While Kuya Silver’s Bethania mine and infrastructure reported no measurable impact from the July 19th 5.5 magnitude earthquake in the Junin region, we recognize the severe toll this seismic event has taken on the surrounding towns and districts, particularly in the district of Chongos Bajo and the highly affected area of Chupuro. Kuya Silver extends its deepest sympathies to the people of Junin and is actively working to support recovery efforts.

As part of our commitment to our local workforce and neighboring populations, Kuya Silver is providing direct assistance to our employees who have family members in the affected areas. Furthermore, the Company is making direct donations to support the local emergency relief efforts.

For our partners, contractors, and stakeholders who wish to join these relief efforts, local institutions have established official donation reception centers to support the victims. Donations of drinking water, non-perishable food, warm clothing, and essential medicines are currently being received at the following collection point: Municipalidad Distrital de Chongos Bajo: Main municipal offices.

Quality Assurance and Quality Control

Quality assurance and quality control include two sampling procedures. Underground vein material from stopes are sampled to confirm vein grades and to reconcile against the mine model; and sampling of freshly mined material in stockpiles to determine dilution and the head grade that is sent to the processing plant.

Underground vein sampling was conducted systematically every 4 meters along the galleries. This involved excavating a narrow and continuous channel either parallel to the vein or perpendicular to its orientation. The entire volume of material excavated from the channel was collected as a sample.

Freshly mined material in the stockpiles and concentrate stockpiles were sampled using trenching, a method involving the excavation of narrow trenches perpendicular to the major axis of the pile. Trenches were systematically dug at regular intervals across all depths of the pile. The location of each trench was referenced to a topographic control point and recorded in the sampling log.

All material was carefully collected on plastic sheets, then pulverized at the mine site. The pulverized material was quartered, and one quarter was labeled and secured in vinyl sample bags. The samples were then transported to Dmtri I. Mendelejeff laboratory in Huancayo for processing using fire assay followed by atomic absorption spectroscopy (AAS).

All concentrate assay results are cross-checked against independent analyses conducted by the buyer. Furthermore, sample security protocols include sealed trucks for transporting run-of-mine (ROM) material and concentrate trucks with tamper-proof devices with safety seals, and a documented custody chain overseen by the mine superintendent (Bethania).

National Instrument 43-101 Disclosure

The technical content of this news release has been reviewed and approved by Mr. Kevin J. O’Connell, P.E., Independent Technical Advisor to of Kuya Silver and a Qualified Person as defined by National Instrument 43-101.

About Kuya Silver Corporation

Kuya Silver is a Canadian‐based, growth-oriented mining company with a focus on silver. Kuya Silver operates the Bethania silver mine in Peru, while developing district-scale silver projects in mining-friendly jurisdictions including Peru and Canada.

For more information, please contact:

David Stein, President and Chief Executive Officer
Telephone: (604) 398‐4493
[email protected]
www.kuyasilver.com

Reader Advisory

This news release contains statements that constitute “forward-looking information,” including statements regarding the plans, intentions, beliefs, and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may,” “would,” “could,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “must,” “next,” “propose,” “new,” “potential,” “prospective,” “target,” “future,” “verge,” “favorable,” “implications,” and “ongoing,” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking information. Investors are cautioned that statements including forward-looking information are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those described in the forward-looking information as a result of various factors, including but not limited to fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing, and general economic, market, and business conditions. There can be no assurances that such forward-looking information will prove accurate, and therefore, readers are advised to rely on their own evaluation of the risks and uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305919

Release – GeoVax Highlights Strategic Alignment of GEO-MVA with HHS/ASPR’s Five-Year Medical Countermeasure Preparedness Strategy

Posted on by [email protected]

Research News and Market Data on GOVX

ASPR Report Reinforces National Priorities for Domestic Manufacturing, Platform Technologies, Strategic National Stockpile Modernization, and Pandemic Preparedness

ATLANTA, GA – July 21, 2026  – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing next-generation vaccines and immunotherapies, today highlighted the strong alignment between its GEO-MVA vaccine platform strategy and the priorities outlined in the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response’s (ASPR) newly released Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget: Fiscal Years 2025–2029.

The report provides the federal government’s five-year roadmap for investments in medical countermeasures, advanced manufacturing, Strategic National Stockpile (SNS) modernization, and preparedness against emerging infectious disease and biological threats.

According to the report, approximately 65% of future medical countermeasure investment is expected to focus on threat-agnostic and multi-threat technologies, while emphasizing domestic manufacturing capability, scalable vaccine platforms, and sustained preparedness infrastructure. The report also projects a total five-year medical countermeasure investment need of approximately $66.9 billion, underscoring the growing strategic importance of resilient domestic biodefense capabilities.

“The release of ASPR’s five-year preparedness strategy reinforces many of the strategic priorities that have guided our GEO-MVA program,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “The report recognizes that future preparedness requires more than individual vaccines – it requires flexible platform technologies, domestic manufacturing capability, resilient supply chains, and sustainable medical countermeasure infrastructure. GEO-MVA has been developed with these national priorities in mind.”

ASPR Priorities Closely Align with the GEO-MVA Strategy

GeoVax believes several priorities identified in the ASPR strategy directly support the long-term strategic rationale underlying the GEO-MVA program.

Domestic Manufacturing

The ASPR report identifies sustaining and expanding domestic commercial manufacturing capability as one of the nation’s principal preparedness challenges.

GeoVax’s GEO-MVA program is designed to establish a U.S.-based source of Modified Vaccinia Ankara (MVA) vaccine manufacturing, supporting domestic supply-chain resilience while reducing dependence on limited global manufacturing capacity.

Platform Technologies

The report emphasizes investments in threat-agnostic and multi-threat technologies capable of responding rapidly to future public health emergencies.

The MVA vector represents a well-established vaccine platform with demonstrated applicability across multiple infectious disease targets, providing flexibility beyond any single indication.

Strategic National Stockpile

The ASPR strategy calls for continued modernization of the Strategic National Stockpile while addressing lifecycle management, replenishment, and transition of new medical countermeasures into long-term preparedness programs.

GeoVax believes the GEO-MVA program aligns with these objectives by supporting future U.S. preparedness capacity for orthopoxvirus threats.

Emerging Infectious Diseases

The report identifies emerging infectious diseases as among the nation’s highest preparedness priorities while emphasizing investments that enable rapid response to evolving threats.

GeoVax’s clinical development strategy for GEO-MVA is intended to support preparedness against mpox and smallpox while leveraging the broader capabilities of the MVA platform.

Independent Validation of Long-Term Preparedness Trends

The ASPR report reflects a continuing evolution in federal preparedness strategy – from investing primarily in individual products toward investing in strategic capabilities, including manufacturing infrastructure, platform technologies, and sustainable preparedness systems.

GeoVax believes these evolving priorities reinforce the long-term strategic value of domestic vaccine manufacturing capabilities that can support future public health emergency response.

“Preparedness is increasingly being viewed as a strategic national capability rather than simply a collection of products,” added Mr. Dodd. “We believe this evolution supports the importance of maintaining flexible vaccine platforms and domestic manufacturing infrastructure capable of responding to future biological threats.”

About GEO-MVA

GEO-MVA is GeoVax’s Modified Vaccinia Ankara (MVA) vaccine candidate being developed to support protection against mpox and smallpox. The program is advancing through an immunobridging regulatory strategy following positive Scientific Advice from the European Medicines Agency (EMA) and is intended to provide an additional source of MVA vaccine manufacturing capacity supporting future public health preparedness initiatives.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected] 

Release – Lucky Strike Entertainment Unveils Brand Refresh for AMF, Honoring an American Classic Families Have Always Loved

Posted on by [email protected]
Lucky Strike Entertainment Investor Relations site

Research News and Market Data on LUCK

07/21/2026

A Classic Since Always™ – From Revolutionary Pinsetters to Everyday Family Traditions

RICHMOND, Va.–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK) today announced the launch of a refreshed identity for AMF (American Machine & Foundry), one of the most iconic names in American bowling. Rooted in AMF’s 126-year heritage, the rebrand positions the brand for the future and reflects its evolution into a modern bowling destination where families and communities come together for birthday parties, league nights, and social outings.

AMF's refreshed shield logo marks a new chapter for an American classic.

AMF’s refreshed shield logo marks a new chapter for an American classic.

Founded in 1900 as American Machine & Foundry, AMF helped shape modern bowling through innovations, including the automatic pinsetter and the world’s first automatic scoring system. Over the decades, the brand played a significant role in expanding bowling’s popularity across the United States and around the world, helping establish it as one of America’s most participated-in sports. Today, AMF remains a cornerstone of that legacy, welcoming approximately 10.4 million guests annually across more than 80 locations nationwide. With approximately 60 locations planned to transition to the AMF brand, Lucky Strike Entertainment is investing in the brand’s future while building on the foundation that made it an icon of the sport.

The AMF rebrand reflects Lucky Strike Entertainment’s vision to reintroduce AMF as a welcoming “house” with a refreshed identity that still honors the beloved sport. Rooted in AMF’s heritage, AMF destinations will begin to transform with bold new visuals led by Department of Branding and Design (DoBad) that lean into the brand’s ownable red, complemented by supporting tones of varsity blue, heritage white, and gold. The iconic shield logo will be updated with new lettering and bright red hues that will be reflected across digital and physical touchpoints. Consumers will be introduced to the new AMF brand platform, A Classic Since Always™, which celebrates modern bowling experiences while preserving the familiar, dependable atmosphere guests expect. Altogether, these elements position AMF as a timeless neighborhood destination designed to be the top bowling hub in neighborhoods across the country.

“This is more than a brand refresh. It’s an investment in the future of AMF,” said Thomas Shannon, Founder and CEO of Lucky Strike Entertainment. “We are building on the strength of an iconic brand and positioning it for long-term growth. As we expand the AMF brand across the country, our focus remains the same: delivering great bowling experiences, supporting league play, and providing an affordable destination for families and communities.”

Guests will begin to see the new AMF brand across digital platforms, social media, and select in-center materials, with additional updates rolling out over time. Future enhancements will include heritage walls showcasing memorabilia from AMF’s bowling legacy, along with nostalgic, varsity-inspired design elements such as swallowtail pennants and signage. While the look evolves, Lucky Strike Entertainment remains committed to AMF’s high-quality lanes, welcoming atmosphere, and experiences that bring people together, including leagues, open play, youth programs, family celebrations, and premier PBA Tour events such as the Tournament of Champions and AMF PBA World Championships. AMF also continues to offer affordable, value-driven birthday party options, with packages like Family Unlimited and the All Star Package designed to make celebrations easy, convenient, and accessible for families.

As AMF enters its next chapter, Lucky Strike Entertainment remains focused on elevating the traditional neighborhood bowling center, rooted in heritage, shaped by the local community, and designed to create moments of connection for generations to come.

For more information on AMF and AMF locations near you, please visit AMF.com and follow AMF on Instagram, and Facebook.

About Lucky Strike Entertainment

Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit LuckyStrikeEnt.com.

Media:
[email protected]

Source: Lucky Strike Entertainment Corporation

Release – Kratos Receives Mobile Counter-Unmanned Aircraft System(C-UAS) Approximate $156 Million Single Award Contract by U.S. Department of Energy Office of Secure Transportation

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

July 21, 2026

PDF VersionKratos to provide Mobile Counter-Unmanned Aircraft System (C-UAS) Platforms Designed to Support Critical National Security Mission

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced it has been awarded a sole-source, single award Indefinite Delivery/Indefinite Quantity (IDIQ) contract for approximately $156 million, by the U.S. Department of Energy’s National Nuclear Security Administration (NNSA) Office of Secure Transportation (OST), in support of Project Solar Shield.

Under this new contract award, Kratos will provide mobile Counter-Unmanned Aircraft System (C-UAS) platforms designed to support OST’s critical National Security mission. The Office of Secure Transportation is responsible for the safe and secure ground and air transportation of nuclear weapons, weapon components, and special nuclear materials, as well as other missions supporting U.S. national security.

To address emerging threats to these operations, OST requires a mission-ready mobile platform capable of detecting, tracking, identifying, and responding to potentially hostile unmanned aircraft systems in real time. Unlike traditional fixed-site defense infrastructure, Project Solar Shield is designed to provide a dynamic mobile C-UAS capability that can support mission requirements wherever OST operations occur. The program will leverage commercial and government best-in-class C-UAS technologies, to provide a layered defense posture supporting OST personnel and mission requirements.

Kratos was selected following a rigorous technical evaluation and was identified as the provider capable of meeting OST’s technical, cost, schedule, operational, safety, redundancy, integration, and long-term sustainment requirements. Kratos’ engineer-to-order approach combines C-UAS system, mobile platform design, command-and-control, and advanced power management technologies into a fully integrated solution, built for demanding threat and mission environments.

“Project Solar Shield represents a significant milestone for Kratos and the broader government C-UAS market,” said Dave Carter, President of Kratos’ Defense & Rocket Support Services Division. “As the first large scale government production contract of its kind built around this integrated approach, the program demonstrates the value of combining C-UAS, mobile platform design, command-and-control capabilities, and resilient power management into a single mission-ready solution. The resulting platform provides OST with a highly modular and scalable mobile C-UAS capability, designed to support evolving mission requirements across the continental United States.”

Eric DeMarco, President and CEO of Kratos, said, “We believe that Kratos’ technology, system and integration capabilities in the C-UAS mission area are industry leading, and also our ability to mass produce large quantities of relevant systems at an affordable cost. Our entire organization is proud to have received this program award to protect and secure critical United States assets and infrastructure.”

Work under this new program award will be performed at secure Kratos facilities. Due to security-related and other considerations, no additional information will be provided related to this contract award. Work under the contract is expected to begin immediately.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Posted on by [email protected]
Primary Logo

Research News and Market Data on CVDK

  • Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions
  • Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin
  • Recently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia

PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, the Company has initiated a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets.

Cadrenal has assembled multiple late-stage critical care cardiovascular assets designed to address serious conditions for which existing treatment options remain inadequate. This capital-efficient operational model addresses a large, unserved therapeutic whitespace, unlocking substantial cumulative platform potential. The strategy positions Cadrenal’s assets as high-value additions which may be capable of delivering immediate value to the pipelines of global companies across rare disease therapies, critical care cardiology, and cardiac intensive care unit (CICU) medical products.

The strategic alignment of the Cardiac Acute Critical Care Franchise organizes Cadrenal’s portfolio into three high-value commercial pillars:

  • Pillar 1: Pre-Operative Safety (Frunexian IV): An IV Factor XIa inhibitor for heparin-induced thrombocytopenia (HIT)-susceptible patients undergoing coronary artery bypass graft (CABG) surgery, designed to replace unpredictable alternative protocols. Phase 2-ready.
  • Pillar 2: Orphan Regulatory Acceleration (including Tecarfarin for Kawasaki Disease): Leveraging substantial commercial tailwinds, fee waivers, and potential seven-year market exclusivity associated with the potential Orphan Drug Designation (ODD) pathways for cardiac surgery patients. Phase 3-ready.
  • Pillar 3: Post-Operative Shield (CAD-1005): A Phase 3-ready IV 12-LOX inhibitor designed to target platelet hyperactivation and thrombotic risk in patients with post-operative Heparin-Induced Thrombocytopenia (HIT). Secondary benefits may include blocking the inflammatory 12-HETE cascade to reduce cardiac surgery-associated acute kidney injury (CSA-AKI).

This franchise framework is strongly supported by the impressive clinical data presented earlier this month at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris. The late-breaking Phase 2 data for CAD-1005 demonstrated a compelling medical profile, with a greater than 25% absolute reduction in thrombotic events and a favorable safety and renal-protective baseline.

“Our landmark clinical data presentation at ISTH 2026 has validated the mechanisms and the immense medical value of our Cardiac Acute Critical Care Franchise,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “By organizing our pipeline into three distinct commercial pillars, we are positioning Cadrenal to maximize asset value. Transitioning to a partnership-driven business model enables us to map a direct, efficient path to commercialization alongside global industry leaders.”

In tandem with this strategic focus, the Company is advancing updates to its clinical pipeline for tecarfarin, highlighting its distinct carboxylesterase-1 (CES-1)-mediated metabolism, which helps avoid dangerous drug-drug interactions. This includes expanding clinical protocols to rare pediatric disease indications, such as giant coronary artery aneurysms (CAAs) caused by Kawasaki Disease-potentially qualifying the asset for a high-value, open-market Priority Review Voucher (PRV)-while continuing to support established indications in End-Stage Kidney Disease (ESKD) and Left Ventricular Assist Devices (LVADs).

Standalone Platform Expansion: Oral 12-LOX (CAD-2000)

Beyond the Cardiac Acute Critical Care Franchise, Cadrenal is advancing its preclinical platform asset, CAD-2000, a highly selective, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor designed to treat chronic cardiorenal inflammatory and thrombotic indications. CAD-2000 serves as a potent oral follow-on companion to the Company’s IV acute care platform, potentially enabling prospective partners to capture extended market share across both acute inpatient settings and chronic outpatient follow-up care.

About CAD-1005

CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. To view how CAD-1005 is intended to work in patients with HIT, click https://vimeo.com/1209382706/7dde06dc08?share=copy&fl=sv&fe=ci

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The Company’s Cardiac Acute Critical Care Franchise also includes frunexian, an investigational intravenous Factor XIa inhibitor designed to provide anticoagulation for patients undergoing major cardiac surgery.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. Tecarfarin has also received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA).

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements such as Cadrenal launching a partnering process; advancing its Cardiac Acute Critical Care Assets to transaction readiness following landmark ISTH data presentation; the Company’s capital-efficient strategy focusing on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions; the Company exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin; the Company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions; the Company securing strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets; Cadrenal’s multiple late-stage critical care cardiovascular assets addressing serious conditions for which existing treatment options remain inadequate; the capital-efficient operational model addressing a large, unserved therapeutic whitespace, unlocking substantial cumulative platform potential; Cadrenal’s assets delivering immediate value to the pipelines of global companies across rare disease therapies, critical care cardiology, and cardiac intensive care unit (CICU) medical products; frunexian IV successfully replacing unpredictable alternative protocols; the potential of CAD-1005 to block the inflammatory 12-HETE cascade to reduce cardiac surgery-associated acute kidney injury; positioning Cadrenal to maximize asset value; transitioning to a partnership-driven business model enabling the Company to map a direct, efficient path to commercialization alongside global industry leaders; the Company advancing updates to its clinical pipeline for tecarfarin, highlighting its distinct carboxylesterase-1 (CES-1)-mediated metabolism, which helps avoid dangerous drug-drug interactions; expanding clinical protocols to rare pediatric disease indications, such as giant coronary artery aneurysms (CAAs) caused by Kawasaki Disease-potentially qualifying the asset for a high-value, open-market Priority Review Voucher (PRV)-while continuing to support established indications in End-Stage Kidney Disease (ESKD) and Left Ventricular Assist Devices (LVADs); Cadrenal advancing its preclinical platform asset, CAD-2000, a highly selective, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor designed to treat chronic cardiorenal inflammatory and thrombotic indications. CAD-2000 serves as a potent oral follow-on companion to the Company’s IV acute care platform, potentially enabling prospective partners to capture extended market share across both acute inpatient settings and chronic outpatient follow-up care; tecarfarin potentially treating patients with Kawasaki disease (KD). Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to enter into a partnership opportunity, development, licensing and commercialization for CAD-1005 frunexian, and tecarfarin; the ability of Cadrenal’s assets to be additions to the pipelines of global companies across rare disease therapies, critical care cardiology, and cardiac intensive care unit medical products; the ability to benefit from the commercial potential of the Cadrenal’s product candidates; the ability to raise sufficient capital to continue the clinical development of its product candidates; and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, [email protected]

Release – CVG Announces Second Quarter 2026 Earnings Call

Posted on by [email protected]
CVG-Corporate

Research News and Market Data on CVGI

July 21, 2026

NEW ALBANY, Ohio, July 21, 2026 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Tuesday, August 4, 2026, at 8:30 a.m. ET, to discuss second quarter 2026 financial results. CVG will issue a press release and presentation prior to the conference call.
        
Toll-free participants dial (833) 461-5787 using conference code 592968497. International participants dial (585) 542-9983 using conference code 592968497. This call is being webcast and can be accessed through the “Investors” section of CVG’s website at ir.cvgrp.com where it will be archived for one year.

About CVG

Commercial Vehicle Group, Inc. and its subsidiaries, is a global provider of systems, assemblies and components to global commercial vehicle markets and electric vehicle markets. We deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

Investor Relations Contact:
Ross Collins or Nathan Skown
Alpha IR Group
[email protected]                                                                                                                                                                                                                                                                                                                                                       

Primary Logo

Source: Commercial Vehicle Group, Inc.

Release – FreightCar America, Inc. Continues Aftermarket Expansion with Acquisition of Leading Regional Distributor

Posted on by [email protected]
FreightCar America

Research News and Market Data on RAIL

07/21/2026

CHICAGO, July 21, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that it has completed the acquisition of Southern Parts & Equipment, Inc. (“SP&E”), a longstanding distributor of new, used and reconditioned railcar parts and equipment. The transaction marks the Company’s second acquisition in the railcar aftermarket space within the past year.

The acquisition further expands FreightCar America’s aftermarket distribution capabilities and strengthens the Company’s ability to serve customers with a broader offering of railcar components and related services. Southern Parts & Equipment has built a long-standing presence in the rail industry, supplying railcar parts and equipment and supporting customers with rail industry consulting, inspections and project-related services.

“Southern Parts & Equipment is a highly complementary addition to our growing aftermarket platform,” said Nicholas Randall, President and Chief Executive Officer of FreightCar America. “This acquisition further strengthens our ability to support customers with improved access to critical railcar components, while advancing our strategy to build complementary aftermarket capabilities that increase the value we deliver across the railcar lifecycle.”

“We are excited to welcome Southern Parts & Equipment to FreightCar America,” said Michael Riordan, Vice President, Chief Financial Officer & Treasurer of FreightCar America. “Southern Parts & Equipment brings valuable customer relationships, product knowledge and sourcing capabilities that align well with our aftermarket growth strategy. By combining its capabilities with FreightCar America’s commercial reach, supply chain discipline and growing aftermarket platform, we believe we can deliver greater value to customers while continuing to scale a more diversified and recurring revenue stream. This transaction is consistent with our disciplined capital allocation framework and is expected to be immediately accretive to FreightCar America.”

About Southern Parts & Equipment

Founded in Monroe, Georgia, Southern Parts & Equipment supplies new, used and reconditioned railcar parts and equipment to the railroad industry. The company serves repair shops, railroads, private car owners and other industrial customers, and has earned a decades-long reputation as a trusted source for railcar components. To learn more about Southern Parts & Equipment, visit www.southernrailparts.com.

About FreightCar America

FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.

Forward-Looking Statements

This press release may contain statements relating to our expected financial performance, financial condition, and/or future business prospects, events and/or plans that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. These risks and uncertainties relate to, among other things, the cyclical nature of our business; adverse geopolitical, economic and market conditions, including inflation; material disruption in the movement of rail traffic for deliveries; fluctuating costs of raw materials, including steel and aluminum; delays in the delivery of raw materials; our ability to maintain relationships with our suppliers of railcar components; our reliance upon a small number of customers that represent a large percentage of our sales; the variable purchase patterns of our customers and the timing of completion; delivery and customer acceptance of orders; the highly competitive nature of our industry; the risk of lack of acceptance of our new railcar offerings; potential unexpected changes in laws, rules, and regulatory requirements, including tariffs and trade barriers (including recent United States tariffs imposed or threatened to be imposed on China, Canada, Mexico and other countries and any retaliatory actions taken by such countries); and other competitive factors. The factors listed above are not exhaustive. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

Investor Contact:[email protected]



Primary Logo

Source: FreightCar America, Inc.

Why Oracle Stock Has Lost Half Its Value in Six Weeks

Posted on by [email protected]

Nine months ago, Oracle was the hottest stock in enterprise technology. On September 10, 2025, shares surged 36% in a single session after reports surfaced that OpenAI had committed to a $300 billion, five-year cloud computing deal with the company. The stock hit a record high of $345.72. The narrative was irresistible: Oracle had reinvented itself as an AI infrastructure company, and the biggest name in artificial intelligence had just bet hundreds of billions on that transformation.

Today, Oracle trades below $140. The stock has fallen more than 50% from its June 2026 high and roughly 62% from last September’s peak. What happened in between is a story about what goes wrong when a company takes on enormous financial risk to chase AI demand that may not materialize as quickly, or as reliably, as the contracts suggest.

The Numbers That Spooked the Market

Oracle’s fiscal 2026 results, released in June, contained strong headline numbers. Revenue grew. Earnings beat estimates. Cloud infrastructure revenue surged 93% year over year in Q4. Under normal circumstances, those would be the kind of results that lift a stock. Instead, shares fell more than 12% in a single session after the report because of what the financial statements revealed underneath the growth.

Capital expenditures for the fiscal year surged to approximately $56 billion, a 162% increase from the prior year. That spending pushed Oracle into negative free cash flow of roughly $24 billion. Total debt swelled to approximately $130 billion. Management indicated that spending would remain elevated, with approximately $70 billion in capex planned for fiscal 2027, and floated the possibility of additional debt and equity raises to fund the buildout. The company’s CFO warned that gross margins would decline in fiscal 2027 as new data center projects ramp up.

The OpenAI Concentration Problem

The risk that has rattled investors most is customer concentration. Oracle ended fiscal 2026 with $638 billion in remaining performance obligations, a 363% increase from $138 billion a year earlier. That figure represents signed contracts for services not yet delivered, and on its face it looks like an extraordinary demand signal. The concern is who those contracts belong to.

Approximately $300 billion of Oracle’s RPO is reportedly attributable to OpenAI alone. OpenAI generates roughly $25 billion in annualized revenue and continues to operate at a significant loss, relying on outside investors to fund its operations. When OpenAI announced earlier this summer that it would delay its IPO from 2026 to 2027, Oracle shares dropped 9% in a single week because the delay raised questions about whether OpenAI would have the financial capacity to honor the scale of its commitments.

Oracle’s own annual report contained unusually thorough risk disclosures about the possibility that its largest AI infrastructure customers might not be able to fulfill their obligations. For a company carrying $130 billion in debt to build data centers designed to serve those exact customers, that warning landed with force.

What This Tells the Broader Market

For investors tracking the AI infrastructure buildout, Oracle’s decline is not an indictment of AI demand itself. It is a case study in concentration risk, leverage, and the gap between signed contracts and delivered revenue. The demand for AI compute capacity is real and growing. But the financial structures being built to serve that demand carry meaningful risk when they depend heavily on a small number of customers whose own economics remain unproven.

Smaller cloud infrastructure, data center, and AI services companies with more diversified customer bases and conservative balance sheets face a fundamentally different risk profile. The AI infrastructure buildout is not slowing down. But Oracle’s 50% decline is a reminder that how a company finances its participation in that buildout matters as much as the demand itself.

T3 Defense (DFNS) – Stock Split Complete

Posted on by [email protected]


Tuesday, July 21, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Reverse Stock Split. As outlined in prior reports, T3 underwent a 1-for-125 reverse stock split to regain compliance with Nasdaq regulations. As a result, the number of outstanding shares declined from approximately 139.8 million to approximately 1.1 million. We adjusted our model to reflect the impact on earnings per share.

Impact. Assuming the stock split only impacts the forward quarters, the 2Q adjusted net loss increases to $2.87/sh, 3Q to a loss of $2.16/sh, and 4Q to a net loss of $1.75/sh, up from a previous projected net loss of $0.06/sh, $0.03/sh, and $0.02 per share, respectively, Full year net loss increases to $3.90/sh, up from a prior full year net loss forecast of $0.50/sh. If we adjusted 1Q26 EPS loss to the 1.1 million outstanding shares, full-year net loss rises to $30.26/sh, which includes a number of one-time non-cash charges. The share change does not impact our estimates for adjusted EBITDA, which remains at a loss of $6 million for 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – Further Expansion in the Defense Industry

Posted on by [email protected]


Tuesday, July 21, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contract Manufacturing. NN continues to expand into new and adjacent segments, providing the Company with strong growth opportunities, in our view. Most recently, NN successfully entered the Tier 1 contract manufacturing industry for firearm components in the United States market.

Details. NN’s contract manufacturing agreement is to mass-produce completed firearms products for a leading provider of firearms products in the U.S. This new business begins in the third quarter and will continue ramping up through 2028. This new business is expected to add between $12 million and $15 million in sales. Due to the multipart complexity of this new product line, these products are now the highest-priced products in the Company’s portfolio of new products.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Greenwich LifeSciences, Inc. (GLSI) – Modifications To Phase 3 FLAMINGO-01 Trial Raise Probability Of Success

Posted on by [email protected]


Tuesday, July 21, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Trial Modifications Announced. Greenwich Pharmaceuticals announced modifications to the Phase 3 FLAMINGO-01 trial testing GLS-100 for the prevention of recurrent breast cancer. Several changes reflect preliminary findings and allow for increased enrollment in the pivotal arm of the trial. We believe the changes increase the likelihood of positive results in the interim and the final analyses, as well as potentially doubling the market.

The Original Phase 3 Design. The original trial design screened patients for HLA type, an immune system classification. Patients with HLA-A*02, the most common type, were randomized into two double-blind arms testing GLSI-100 against a placebo control. The non-HLA-A*02 patients were entered into an open-label arm. Following the standard of care treatment for breast cancer, patients were given six monthly doses of GLSI-100, then boosters every 6 months for 11 total doses.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Lockheed Martin Unveiled a Patriot Missile That Costs Half as Much. The Real Story Is What It Means for the Defense Supply Chain

Posted on by [email protected]

Lockheed Martin introduced a new, lower-cost version of its Patriot interceptor at the Farnborough Airshow on Monday, a move that reflects how fundamentally the economics of air defense have changed under the pressure of real-world conflict. The PAC-3 Adapted Capability Effector, or PAC-3 ACE, is projected to cost less than half the price of the current PAC-3 MSE interceptor, which runs approximately $4 million per missile according to US Army budget documents. Initial production is expected to begin within 36 months, developed and manufactured jointly with US and European industry partners.

The announcement is not just a product launch. It is a direct response to a cost asymmetry problem that the Iran conflict has made impossible to ignore.

The Math That Forced the Decision

Throughout Operation Epic Fury, US forces in the Middle East have burned through finite interceptor stockpiles to counter Iranian drones that cost a fraction of the missiles used to destroy them. A single PAC-3 MSE interceptor costs roughly $4 million. An Iranian Shahed drone costs approximately $35,000. When you are spending more than 100 times the cost of the threat to defeat it, the economics of attrition work against you regardless of how effective the technology is.

That disparity has pushed the Pentagon and its prime contractors to rethink the entire approach to air defense procurement. The Missile Defense Agency launched a Low-Cost Interceptor program in late 2025 with a target price of $750,000 per unit. Lockheed’s PAC-3 ACE, at under $2 million, sits in the middle of the cost spectrum between that target and the current MSE, offering a bridge solution that can enter production faster because it is built on existing PAC-3 guidance technology and is compatible with legacy Patriot systems and the Integrated Battle Command System.

The European Manufacturing Push

Lockheed is not building this missile alone. The company has signaled its intention to develop PAC-3 ACE jointly with European defense partners and has expressed interest in eventually producing an entirely European-sourced variant manufactured on the continent. This follows a July 7 memorandum of understanding with German arms manufacturer Rheinmetall to establish the first European production center for the Army Tactical Missile System.

The pattern is clear: Lockheed is investing in distributed manufacturing capacity across allied nations rather than concentrating production domestically. That approach strengthens the broader defense industrial base, reduces supply chain bottlenecks, and gives NATO members the ability to produce and stockpile interoperable interceptors locally rather than depending entirely on American production during a crisis.

Where Small Cap Defense and Industrial Companies Fit

For investors tracking the defense and industrial sectors below the $2 billion market cap threshold, the shift toward distributed, cost-optimized defense manufacturing creates a meaningful opportunity set. When a prime contractor like Lockheed commits to building cheaper weapons with a broader supplier base across multiple countries, it pulls smaller specialized manufacturers, component suppliers, and defense services companies into the production chain.

Defense services contractors like V2X, which provides mission-critical support across military operations and logistics, and specialized defense technology companies like T3 Defense sit in the exact part of the ecosystem that benefits when defense procurement scales horizontally rather than concentrating vertically through a single prime. Precision component manufacturers like NN Inc., which produces highly engineered parts for defense and industrial applications, are also positioned in the supply chain that affordable, high-volume interceptor production would activate.

The defense industry spent decades optimizing for performance at any cost. The Iran conflict exposed that model’s limitations in real time. What comes next is a manufacturing and procurement shift toward affordability, volume, and distributed production, and the smaller companies with the right capabilities are the ones best positioned to fill the gaps the primes cannot fill alone.

Release – T3 Defense Subsidiary ITS Delivers Advanced Composite Materials Production Line to Leading Building Materials Manufacturer, Bringing Defense-Proven Fiberglass Technology to Industrial Scale

Posted on by [email protected]

Research News and Market Data on DFNS

ITS Designs and Delivers a Custom Composite Materials Production Line, Extending Defense-Grade Fiber-Reinforced Composite Manufacturing to Industrial Scale

July 20, 2026 09:00 ET  | Source: T3 Defense Inc.

NEW YORK and NETANYA, Israel, July 20, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense and industrial businesses, today announced that its subsidiary, Industrial Techno-Logic Solutions (“ITS”), has designed and delivered a custom composite materials production line to a leading Israeli building materials manufacturer.

Bringing its defense-proven fiberglass production expertise to a line for a customer in building materials, ITS was able to fully integrate automated materials handling, precision application, and fiberglass-based reinforcement to manufacture advanced composite products at industrial scale. Applying its Design for Manufacturing (DFM) methodology, ITS assumed end-to-end responsibility for mechanical engineering design, machining, supply chain management, integration, and factory deployment, enabling the manufacturer to achieve production-ready output with the precision and delivery reliability that characterizes ITS’s work across defense and industrial programs.

ITS composites manufacturing

“Defense capability increasingly depends on sovereign manufacturing supply chains. Nations that cannot produce the components their defense programs require at home face critical vulnerabilities at exactly the wrong moment. ITS is closing that gap,” said Menny Shalom, Chairman and CEO of T3 Defense. “Composite materials are becoming foundational across defense and industrial manufacturing, and the ability to produce them reliably at scale is a strategic capability in its own right. This production line gives the customer exactly that foundation, at the precision that defense and industrial programs demand. As governments and prime contractors continue to prioritize localized, qualified manufacturing, we expect ITS to be an increasingly sought-after partner for exactly this type of capability-building engagement.”

The delivery marks the latest milestone in an ongoing relationship between ITS and the undisclosed customer, reflecting confidence the customer has placed in ITS as a long-term manufacturing partner. The expansion of the collaboration to include a dedicated continuous production line underscores ITS’s ability to support customers across successive programs and scale, translating early-stage engineering partnerships into full production-ready industrial infrastructure.

About ITS

Industrial Techno-Logic Solutions (ITS) is an engineering and manufacturing systems company that develops specialized production lines for complex defense and industrial technologies. Using a Design for Manufacturing (DFM) methodology, ITS designs production systems that enable advanced products to be manufactured reliably and at scale. By combining engineering design, machining, supply chain management, and factory deployment, ITS helps customers move technologies from concept to production-ready manufacturing environments. ITS is a majority-owned subsidiary of T3 Defense Inc. For more information, visit www.its-eng.com.

About T3 Defense

T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses embedded in long-cycle national security programs. The company targets businesses operating at constrained, qualification-driven, or execution-critical points across the industrial base where strategic value exists and where qualification, capacity, and execution are decisive. Through disciplined M&A, centralized capital and strategy, and decentralized operating autonomy, T3 Defense seeks to strengthen critical defense capabilities and compound long-term value. For more information, visit www.t3dfns.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding ITS’s engineering and manufacturing capabilities, the expected performance of the production line delivered to the client, and the Company’s growth strategy. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. T3 Defense Inc. undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Contact:

T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

ITS Inc.
Amit Cwitk
[email protected]

Investor Relations (US)
Lena Cati
[email protected]
+1 212 836-9611

Val Ferraro
[email protected]
+1 212 836-9612

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a8ef911-21c5-41ff-836e-ced801f68e93